Earnings Summary

Nurix Therapeutics Inc’s revenue jumped 30.74% since last year same period to $16.59Mn in the Q1 2024. On a quarterly growth basis, Nurix Therapeutics Inc has generated 9.41% jump in its revenue since last 3-months.

Nurix Therapeutics Inc’s net profit fell -17.5% since last year same period to $-41.52Mn in the Q1 2024. On a quarterly growth basis, Nurix Therapeutics Inc has generated 1.04% jump in its net profits since last 3-months.

Nurix Therapeutics Inc’s net profit margin jumped 10.13% since last year same period to -250.33% in the Q1 2024. On a quarterly growth basis, Nurix Therapeutics Inc has generated 9.55% jump in its net profit margins since last 3-months.

Nurix Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.67 - a 16.25% jump from last quarter’s estimates.

Nurix Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.67.

Nurix Therapeutics Inc’s earning per share (EPS) fell -1.33% since last year same period to -0.76 in the Q1 2024. This indicates that the Nurix Therapeutics Inc has generated -1.33% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Nurix Therapeutics Inc’s return on assets (ROA) stands at -0.29.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Nurix Therapeutics Inc’s return on equity (ROE) stands at -0.65.